has developed an accurate and flexible diagnostic assay
called the Thrombus Precursor Protein
test. TpP measures blood levels of soluble fibrin,
which is the immediate precursor to a key component
of blood clots. This FDA approved test aids in the risk
assessment of thrombosis (blood clot formation) in conditions
such as deep vein thrombosis, pulmonary embolism and
myocardial infarction and monitor anticoagulant therapy.
TpP offers physicians the right information at the right
time, and allows them to make the vest possible treatment
decision. It is estimated that the worldwide market
for the TpP test is 350 million tests annually.
More than 5 million people present to emergency
rooms annually with chest pain, but only 15% are actually
experiencing a myocardial infarction.
Some 600,000 patients develop pulmonary embolism
(PE) and 60,000 die of PE annually. This exceeds the
number of American women who die each year of breast
PE is now the most frequent cause of death
associated with childbirth.
Deep-vein thrombosis (DVT) occurs in 2 million
Americans each year, and patients with DVT are prone
to recurrent episodes, increasing mortality risk,
cost, and hospitalization
High-risk procedures for PE/DVT include:
ΡΡ Coronary Artery
Transluminal Coronary Angioplasty
Early detection of life threatening conditions
such as acute MI provides physicians with an important
window of opportunity during which life-saving drugs
can be administered.
Even more clinical trials are currently underway
trials that will further highlight the advantages
of TpP over competing tests, while continuing to raise
the test's profile among hematologists, cardiologists,
emergency room physicians and laboratory technologists.